Inducible Promoter Sequences for Dynamic Gene Expression Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for neurodegenerative diseases lack the ability to regulate and dose the expression of therapeutic genes after delivery, specifically turning on and shutting off gene expression, and fail to utilize disease-related molecular events for modulation.
Innovation Solution
Development of isolated promoter sequences with specific nucleic acid lengths and identities, integrated into expression cassettes and vectors, which are functional in transformed cells to activate, enhance, or repress gene expression based on neurodegenerative disease progression, using adeno-associated virus vectors for delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current gene therapy approaches are used, then therapeutic genes can be delivered to target cells, but the expression of therapeutic genes cannot be regulated or dosed after delivery
Solution Approach 1:
The patent employs inducible promoter systems that allow dynamic control of therapeutic gene expression. The promoter can be switched between active and inactive states in response to specific inducers (e.g., tetracycline, doxycycline, or other small molecules), enabling the expression level to be adjusted according to therapeutic needs and disease progression.
Solution Approach 2:
The patent utilizes promoter sequences whose activity can be modulated by changing chemical parameters - specifically, the presence or absence of small molecule inducers, changes in inducer concentration, or environmental conditions. This allows precise dosing of therapeutic gene expression by varying these chemical parameters.
2Duration of action of stationary object
If constitutive promoters are used for therapeutic gene expression, then continuous expression is achieved, but the ability to turn on and shut off expression is lost
Solution Approach 1:
The patent implements periodic or pulsatile gene expression control through inducible promoters. Expression can be activated periodically by administering inducers at specific intervals, allowing the therapeutic effect to be delivered in controlled bursts rather than continuously, which can be adjusted based on disease stage and patient response.
Solution Approach 2:
The patent describes systems where gene expression can be monitored and fed back into the control mechanism. By measuring therapeutic protein levels or disease markers, the inducer dosage and timing can be adjusted to maintain optimal expression levels, creating a feedback-controlled therapeutic system.
3Adaptability or versatility
If disease-specific promoter sequences are developed, then gene expression can be modulated according to disease progression, but the complexity of promoter selection and validation increases
Solution Approach 1:
The patent identifies and characterizes promoter sequences that are upregulated in multiple neurodegenerative disease states (e.g., promoters responsive to Huntington's disease, Alzheimer's disease, Parkinson's disease). These universal disease-responsive promoters can be applied across different neurodegenerative conditions, reducing the need for disease-specific promoter development while maintaining adaptability.
Solution Approach 2:
The patent involves cloning and replicating promoter sequences that exhibit disease-responsive behavior. Once a functional disease-responsive promoter is identified, it can be copied and inserted into multiple therapeutic vector constructs, standardizing the complex element and simplifying subsequent applications across different therapeutic genes and delivery systems.
Data Source
Figure 1~2A
Figure 2B~2C
Figure 3~4
AI summary
An isolated promoter sequence comprising a nucleic acid of between 600 and 1700 nucleotides in length having at least 90% identity to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7.